Harvard Medical School, Dana-Farber Cancer Institute, Boston MA 02115-6084, USA.
Best Pract Res Clin Haematol. 2009 Dec;22(4):523-8. doi: 10.1016/j.beha.2009.07.003.
Acute myeloid leukaemia (AML) is a complicated, heterogeneous disease and the prognostic factors may be useful in deciding upon appropriate therapy. Cytogenetic testing at diagnosis yields critical prognostic information, but more refinement in prognosis is required. Within cytogenetic subgroups, further important subgroup definitions are possible based on the mutation status and expression analysis of genes such as C-KIT, FLT3, NPM1 and CEBPA, although defining therapies based on such mutations remains controversial.
急性髓系白血病（AML）是一种复杂的、异质性疾病，预后因素可能有助于决定适当的治疗方法。诊断时的细胞遗传学检测可提供关键的预后信息，但需要进一步细化预后。在细胞遗传学亚组内，还可以根据 C-KIT、FLT3、NPM1 和 CEBPA 等基因突变状态和表达分析进一步定义重要的亚组，尽管基于这些突变定义治疗方法仍存在争议。
